Patent ID: 8663640
Filing Date: 2014-03-04
Classification: A61K,A61P,C07K

Abstract:
1. A method for treatment of cancer in a subject in need thereof that has been subjected to a prior treatment regimen using an anti-human EGFR antibody, said method comprising administering to said subject an antibody composition comprising at least a first anti-human EGFR antibody molecule and a second anti-human EGFR antibody molecule distinct from the first molecule, a. wherein the first anti-human EGFR antibody molecule is selected from the group consisting, b. wherein the second anti-human EGFR antibody molecule is selected from the group consisting of wherein the prior treatment regimen does not use the first antibody molecule, the second antibody molecule, an antibody molecule have light chain CDR1, CDR2 and CDR3 in SEQ ID NO:74 and the heavy chain CDR1, CDR2, and CDR3 in SEQ ID NO:42, or any combination of these antibody molecules.